Skip to content
Screener

Vir Biotechnology, Inc. VIR Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Amgen logo
AmgenAMGN
$0
Gilead Sciences logo
Gilead SciencesGILD
$1M
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.16M+464%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Biohaven logo
BiohavenBHVN
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.5B+153%
Enterprise value$1.31B+235%
P/S-26.3×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemValuation HierarchyJune 30, 2026 / Amortized CostJune 30, 2026 / Gross Unrealized Holding GainsJune 30, 2026 / Gross Unrealized Holding LossesJune 30, 2026 / Aggregate Fair Value
Asset-backed securitiesLevel 267,47447(44)67,477
Corporate bondsLevel 2247,600103(309)247,394
Equity securitiesLevel 1N/AN/AN/A4,133
Total financial assets$952,734$192$(1,706)$955,353
Reconciliation to cash, cash equivalents and investments on condensed consolidated balance sheet
Minus: Restricted cash equivalents invested in money market funds(7,923)
Plus: Cash deposits60,312
Total cash, cash equivalents and investments$1,007,742

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s unrealized losses on investments (before tax)?
Vir Biotechnology, Inc. (VIR) reported unrealized losses on investments (before tax) of $1.71M in Q2 2026.
How has Vir Biotechnology, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
Vir Biotechnology, Inc.'s unrealized losses on investments (before tax) increased by 3118.9% year-over-year, from $53K to $1.71M.
What is the long-term trend for Vir Biotechnology, Inc.'s unrealized losses on investments (before tax)?
Over 2 years (2023 to 2025), Vir Biotechnology, Inc.'s unrealized losses on investments (before tax) has grown at a -60.8% compound annual growth rate (CAGR), from $130K to $20K.
What does unrealized losses on investments (before tax) mean?
The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.

Ask your AI about Vir Biotechnology, Inc.'s unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude